Orchid Pharma

Market Cap: Small Cap
Industry: Pharmaceuticals & Drugs
ISIN: INE191A01027
NSEID: ORCHPHARMA
BSEID: 524372

INR

727.95

22.95 (3.26%)

BSENSE

Apr 11, 12:53 PM

BSE+NSE Vol: 43.35 k

Click here to access the older version

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Divi's Lab.

RPG LifeScience.

Cipla

Sun Pharma.Inds.

Torrent Pharma

Aarti Drugs

Gufic BioScience

Sequent Scien.

Dishman Carbogen

Mankind Pharma

Orchid Pharma

Why is Orchid Pharma Ltd ?

Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 4.93%

Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 1.33

The company has declared negative results in Dec'2024 after 2 consecutive positive quarters

PBT LESS OI(Q) At Rs 13.96 cr has Fallen at -28.9% (vs previous 4Q average)
PAT(Q) At Rs 20.78 cr has Fallen at -30.1% (vs previous 4Q average)
OPERATING PROFIT TO INTEREST (Q) Lowest at 6.94 times

Stock is technically in a Bearish range

The technical trend has deteriorated from Mildly Bearish on 10-Mar-25 and has generated -20.83% returns since then
Multiple factors for the stock are Bearish like MACD, Bollinger Band and KST

With ROE of 9.7, it has a Expensive valuation with a 2.9 Price to Book Value

The stock is trading at a discount compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of -37.22%, its profits have fallen by -11.4%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Drugs)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Orchid Pharma for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Orchid Pharma

-37.22%

-0.68

54.66%

SENSEX

0.45%

0.03

14.48%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

19.51%

EBIT Growth (5y)

29.81%

EBIT to Interest (avg)

1.33

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

0.53

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

21.52%

ROCE (avg)

-1.52%

ROE (avg)

4.93%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.92

EV to EBIT

41.62

EV to EBITDA

29.61

EV to Capital Employed

3.05

EV to Sales

3.88

PEG Ratio

Dividend Yield

ROCE (Latest)

8.07%

ROE (Latest)

9.72%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

Bullish

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

2What is working for the Company

PAT(9M)

At Rs 77.37 cr has Grown at 31.96%

-14What is not working for the Company

PBT LESS OI(Q)

At Rs 13.96 cr has Fallen at -28.9% (vs previous 4Q average

PAT(Q)

At Rs 20.78 cr has Fallen at -30.1% (vs previous 4Q average

OPERATING PROFIT TO INTEREST (Q)

Lowest at 6.94 times

INTEREST(Q)

Highest at Rs 3.80 cr

PBDIT(Q)

Lowest at Rs 26.36 cr.

OPERATING PROFIT TO NET SALES (Q)

Lowest at 12.13%

NON-OPERATING INCOME(Q)

is 37.82 % of Profit Before Tax (PBT

EPS(Q)

Lowest at Rs 4.10

Loading Valuation Snapshot...

Here's what is not working for Orchid Pharma

Profit Before Tax less Other Income (PBT) - Quarterly

At Rs 13.96 cr has Fallen at -28.9% (vs previous 4Q average)

over average PBT of the previous four quarters of Rs 19.63 Cr

MOJO Watch

Near term PBT trend is very negative

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly

At Rs 20.78 cr has Fallen at -30.1% (vs previous 4Q average)

over average PAT of the previous four quarters of Rs 29.75 Cr

MOJO Watch

Near term PAT trend is very negative

PAT (Rs Cr)

Operating Profit to Interest - Quarterly

Lowest at 6.94 times

in the last five quarters

MOJO Watch

The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Interest - Quarterly

Highest at Rs 3.80 cr

in the last five quarters and Increased by 14.11 % (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (Rs cr)

Operating Profit (PBDIT) - Quarterly

Lowest at Rs 26.36 cr.

in the last five quarters

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (Rs Cr)

Operating Profit Margin - Quarterly

Lowest at 12.13%

in the last five quarters

MOJO Watch

Company's efficiency has deteriorated

Operating Profit to Sales

Profit Before Tax less Other Income (PBT) - Quarterly

Lowest at Rs 13.96 cr.

in the last five quarters

MOJO Watch

Near term PBT trend is negative

PBT less Other Income (Rs Cr)

Non Operating Income - Quarterly

is 37.82 % of Profit Before Tax (PBT)

MOJO Watch

The company's income from non business activities is high; which is not a sustainable business model

Non Operating Income to PBT

Earnings per Share (EPS) - Quarterly

Lowest at Rs 4.10

in the last five quarters

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (Rs)